Strides Pharma Science Limited has informed the Exchange regarding a press release dated April 30, 2025, titled "Strides Strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg".
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts more than Nifty Microcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Strides Pharma Science has received USFDA approval for its Celecoxib Capsules in three strengths: 100 mg, 200 mg, and 400 mg. Celecoxib is an anti-inflammatory pain relief medication, commonly prescribed for arthritis and joint pain conditions. The approval strengthens Strides' existing anti-inflammatory product portfolio for the US market. USFDA approval allows the company to commercially manufacture and sell the product in the United States, the world's largest pharmaceutical market. The approval covers multiple dosage strengths, giving Strides flexibility to compete across different prescription segments.
This approval adds a new revenue stream from the US market and strengthens Strides' anti-inflammatory portfolio, potentially supporting future earnings growth. The stock may see positive sentiment, though actual financial impact will depend on the scale of commercial launch and market share gained.